<DOC>
	<DOCNO>NCT01267279</DOCNO>
	<brief_summary>In randomize , double-blind trial , BMD operate proximal femur total hip replacement measure dual-energy x-ray absorptiometry ( DXA ) compare two year patient receive IV ZOL 5 mg infusion ( n = 27 ) placebo ( IV saline infusion ; n = 24 ) two week one year surgery .</brief_summary>
	<brief_title>Effect Zoledronic Acid Femoral Bone Loss Following Total Hip Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients undergo primary elective total hip replacement Osteoporosis ( BMD â‰¤2.5 ) Trauma operate femur , hip revision , femoral dysplasia , trochanteric osteotomy , inflammatory arthritis Severe renal impairment Use medication affect BMD Known sensitivity bisphosphonates Severe dental problem , pregnancy able conceive use reliable birth control method</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>